drugset / Trial / NCT03629639

Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism

NCT03629639 ↗

Phase 4 Unknown 80 enrolled Central South University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Psoriasis and metabolic disorders are well-known mutual comorbidities. The investigators hypothesized metformin can ameliorate both psoriasis and metabolic disorders mainly via gut microbiota modulation. The investigators design a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment of metformin for psoriasis combined with disorders of glucose and lipid metabolism and to explore the role of gut microbiota during the process.

Timeline

Start
2018-09-01
Primary completion
2020-09-01
Completion
2020-12-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg Oral

Indications